Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivo

Cell Stress and Chaperones

Volumn 16, Issue 2, 2011, Pages 181-193

  Papathanassiu, Adonia E ^a   MacDonald, Nicholas J ^a,c   Emlet, David R ^b,e   Vu, Hong A ^a,d  

^a Ergon Pharmaceuticals LLC   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Laboratory of Malaria and Vector Research   (United States)

^d Integrated BioTherapeutics Inc   (United States)

^e Pennsylvania Army National Guard   (United States)

Author keywords

2 Deoxyglucose; Efrapeptin; F1F0 ATPase; Hsp90; Proteasome

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; DEOXYGLUCOSE; EFRAPEPTIN DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; FEMALE; GLYCOLYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DEOXYGLUCOSE; DOWN-REGULATION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; PEPTIDES;

EID: 79951679489     PISSN: 13558145     EISSN: 14661268     Source Type: Journal    
DOI: 10.1007/s12192-010-0231-9     Document Type: Article

References (31)

1. J Adams 2001 Proteasome inhibition in cancer: development of PS-341 Semin Oncol 28 613 619 1:CAS:528:DC%2BD38XjvVSmtQ%3D%3D 10.1016/S0093-7754(01)90034-X 11740819 (Pubitemid 33134421)
2. J Adams 2002 Development of the proteasome inhibitor PS-341 Oncologist 7 1 9 16 1:CAS:528:DC%2BD38XitVCht7Y%3D 10.1634/theoncologist.7-1-9 11854543 (Pubitemid 34151104)
3. RL Aft FW Zhang D Gius 2002 Evaluation of 2-deoxy-d-glucose as a chemotherapeutic agent: mechanism of cell death Br J Cancer 87 805 812 1:CAS:528:DC%2BD38XmvF2ks7o%3D 10.1038/sj.bjc.6600547 12232767 (Pubitemid 35178760)
4. M Braga-Basaria E Hardy R Gottfried KD Burman M Saji MD Ringel 2004 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels J Clin Endoclinol Metab 89 2982 2988 1:CAS:528:DC%2BD2cXmtlKjsL8%3D 10.1210/jc.2003-031767 (Pubitemid 38766397)
5. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 1:CAS:528:DyaL2cXktlaksLk%3D 10.1016/0065-2571(84)90007-4 6382953
6. Chou TC, Talalay P (1987) Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and antagonism of chemotherapeutic agents. In: Harrap KR, Connors TA (eds) New avenues in development cancer chemotherapy, Bristol-Myers symposium series. Academic, New York, pp 37-64
7. J Codony-Servat MA Tapia M Bosch C Oliva J Domingo-Domenech B Mellado M Rolfe JS Ross P Gascon A Rovira J Albanell 2006 Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells Mol Cancer Ther 5 3 665 675 1:CAS:528:DC%2BD28Xitl2ltbg%3D 10.1158/1535-7163.MCT-05-0147 16546981
8. DR Emlet KA Brown DL Kociban AA Pollice CA Smith BB Ong SE Shackney 2007 Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-expression in human breast cancer cell lines Mol Cancer Ther 6 10 2664 2674 1:CAS:528:DC%2BD2sXhtFKltbbI 10.1158/1535-7163.MCT-07-0079 17938260 (Pubitemid 350058147)
9. A Fribley Q Zeng CY Wang 2004 Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells Mol Cell Biol 24 22 9695 9704 1:CAS:528:DC%2BD2cXpslOntrY%3D 10.1128/MCB.24.22.9695-9704.2004 15509775 (Pubitemid 39458799)
10. M Guppy P Leedman X Zu V Russell 2002 Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells Biochem J 364 Pt1 309 315 1:CAS:528:DC%2BD38XktFWhs7c%3D 11988105 (Pubitemid 34538975)
11. M Grover-McKay SA Walsh EA Seftor PA Thomas MJ Hendrix 1998 Role of glucose transporter 1 protein in human breast cancer Pathol Oncol Res 4 2 115 120 1:CAS:528:DyaK1cXlvFOmsLk%3D 10.1007/BF02904704 9654596 (Pubitemid 28394627)
12. M Hochstrasser 1995 Ubiquitin, proteasomes, and the regulation of intracellular protein degradation Curr Opin Cell Biol 7 215 223 1:CAS:528:DyaK2MXkslWhtLY%3D 10.1016/0955-0674(95)80031-X 7612274
13. M Jorda A Morales Z Ghorab G Fernadez M Nadji N Block 2002 HER2 expression in prostatic cancer: a comparison with mammary carcinoma J Urol 168 1412 1414 10.1016/S0022-5347(05)64462-X 12352406 (Pubitemid 35034135)
14. RC Kane PF Bross AT Farell R Pazdur 2003 Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy Oncology 8 508 513 10.1634/theoncologist.8-6-508 (Pubitemid 37467365)
15. HT Kang ES Hwang 2006 2-Deoxyglucose: an anticancer and antiviral therapeutic, but not any more a low glucose mimetic Life Sci 78 1392 1399 1:CAS:528:DC%2BD28XhtlGmurw%3D 10.1016/j.lfs.2005.07.001 16111712 (Pubitemid 43199960)
16. HD Kim A Tomida Y Ogiso T Tsuruo 1999 Glucose-regulated stresses cause degradation of DNA topoisomerase IIa by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells J Cell Physiol 180 97 104 1:CAS:528: DyaK1MXjs1CgsLY%3D 10.1002/(SICI)1097-4652(199907)180:1<97::AID-JCP11>3.0. CO;2-Y 10362022 (Pubitemid 29249717)
17. YS Kim SV Alarcon S Lee MJ Lee G Giaccone L Neckers JB Trepel 2009 Update on Hsp90 inhibitors in clinical trial Curr Top Med Chem 9 15 1479 1492 1:CAS:528:DC%2BC3cXhsFakurc%3D 10.2174/156802609789895728 19860730
18. C Korzeniewski DM Callewart 1983 An enzyme-release assay for natural cytotoxicity J Immunol Methods 64 3 313 320 1:CAS:528:DyaL2cXitFejsg%3D%3D 10.1016/0022-1759(83)90438-6 6199426 (Pubitemid 14243095)
19. SB Krasnoff S Gupta RJ St. Leger JAA Renwick BW Roberts 1991 Antifungal and insecticidal properties of efrapeptins: metabolites of the fungus Tolypocladium niveum J Invertebr Pathol 58 180 188 1:CAS:528: DyaK38XhslWltQ%3D%3D 10.1016/0022-2011(91)90062-U
20. M Lerdrup AM Hommelgaard M Grandal B van Deurs 2006 Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way J Cell Sci 119 85 95 1:CAS:528:DC%2BD28XhtFGju78%3D 10.1242/jcs.02707 16352662 (Pubitemid 43169301)
21. G Maschek N Savaraj W Priebe P Braunschweiger K Hamilton GF Tidmarsh LR De Young TJ Lampidis 2004 2-Deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo Cancer Res 64 31 34 1:CAS:528:DC%2BD2cXkslyktQ%3D%3D 10.1158/0008-5472.CAN-03- 3294 14729604 (Pubitemid 38114078)
22. EG Mimnaugh C Chavany L Neckers 1996 Polyubiquitination and proteasomal degradation of the p185-erbB2 receptor protein-tyrosine kinase induced by geldanamycin J Biol Chem 271 37 22796 22801 1:CAS:528:DyaK28Xlslags78%3D 10.1074/jbc.271.37.22796 8798456 (Pubitemid 26304727)
23. 0-ATP synthase functions as a co-chaperone of Hsp90-substrate protein complexes Biochem Biophys Res Commun 345 1 419 429 1:CAS:528: DC%2BD28XkslSmsL8%3D 10.1016/j.bbrc.2006.04.104 16682002
24. HR Park A Tomida S Sato Y Tsukumo J Yun T Yamori Y Hayakawa T Tsuruo K Shin-ya 2004 Effect on tumor cells of blocking survival response to glucose deprivation J Natl Cancer Inst 96 1300 1310 1:CAS:528:DC%2BD2cXnsVyht7g%3D 10.1093/jnci/djh243 15339968 (Pubitemid 39264119)
25. NM Pedersen IH Madshus C Haslekås E Stang 2008 Geldanamycin-induced downreguation of ErbB2 from plasma membrane is clathrin dependent but proteasomal activity independent Mol Cancer Res 6 3 491 500 1:CAS:528: DC%2BD1cXjtFaksb0%3D 10.1158/1541-7786.MCR-07-0191 18337455 (Pubitemid 351416539)
26. RR Ramsay BAC Ackrell CJ Coles TP Singer GA White GD Thorn 1981 Reaction site of carboxanilides and of thenoyltrifluoroacetone in complex II Proc Natl Acad Sci USA 78 825 828 1:CAS:528:DyaL3MXhslSis7s%3D 10.1073/pnas.78.2.825 6940149 (Pubitemid 11159518)
27. V Smith EA Sausville RF Camalier HH Fiebig AM Burger 2005 Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models Cancer Chemother Pharmacol 56 2 126 137 1:CAS:528:DC%2BD2MXksl2gsr8%3D 10.1007/s00280-004-0947-2 15841378 (Pubitemid 40884268)
28. S Sweet G Singh 1995 Accumulation of human promyelocytic leukemic (HL-60) cells at two energetic cell cycle checkpoints Cancer Res 55 5164 5167 1:CAS:528:DyaK2MXpsVartbk%3D 7585566
29. ME Teeter ML Baginsky Y Hatefi 1969 Ectopic inhibition of the complexes of the electron transport system by rotenone, piericidin A, demerol and antimycin A Biochim Biophys Acta 172 2 331 333 1:CAS:528:DyaF1MXosVamtA%3D%3D 10.1016/0005-2728(69)90076-0 4304726
30. W Xu L Neckers 2007 Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells Clin Cancer Res 13 6 1625 1628 1:CAS:528:DC%2BD2sXivV2gsbc%3D 10.1158/1078-0432.CCR-06-2966 17363512 (Pubitemid 46952925)
31. A Zaid R Li K Luciakova P Barath S Nery BD Nelson 1999 On the role of the general transcription factor Sp1 in the activation and repression of diverse mammalian oxidative phosphorylation genes J Bioenerg Biomembr 31 2 129 135 1:CAS:528:DyaK1MXltVOqurc%3D 10.1023/A:1005499727732 10449239 (Pubitemid 29362649)